Nephropathy is a major microvascular complication of diabetes mellitus and often leads to terminal renal failure in addition to contributing significantly to cardiovascular morbidity and mortality. Despites continuous advances, the pathogenesis of diabetic nephropathy remains poorly understood. Recent studies have underscored the significance of structural and functional changes in podocytes in the development and progression of diabetic nephropathy. The role of podocytes in health and diabetic nephropathy and abnormalities including podocyte hypertrophy, effacement, and apoptosis, and a detailed discussion on the role played by the Wnt-β-catenin signaling pathway in podocyte injury and dysfunction are the focus of this review. In addition, the role played by Wnt signaling in mediating the effects of known therapeutic strategies for diabetic nephropathy is also discussed.
XiaoL, WangM, YangS, . A glimpse of the pathogenetic mechanisms of Wnt/β-catenin signaling in diabetic nephropathy. Biomed Res Int2013;2013:1–7.doi:10.1155/2013/987064
2.
RooneyB, O'DonovanH, GaffneyA, . CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett2011;585:531–8.doi:10.1016/j.febslet.2011.01.004
3.
KavanaghDH, SavageDA, PattersonCC, . Association analysis of canonical Wnt signalling genes in diabetic nephropathy. PLoS One2011;6:1–6.doi:10.1371/journal.pone.0023904
4.
KawakamiT, RenS, DuffieldJS. Wnt signalling in kidney diseases: dual roles in renal injury and repair. J Pathol2013;229:221–31.doi:10.1002/path.4121
DaiC, StolzDB, KissLP, . Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol2009;20:1997–2008.doi:10.1681/ASN.2009010019
7.
SaurusP, KuuselaS, LehtonenE, . Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. Cell Death Dis2015;6:1–12.doi:10.1038/cddis.2015.125
8.
LiJJ, KwakSJ, JungDS, . Podocyte biology in diabetic nephropathy. Kidney Int Suppl2007;106:36–42.doi:10.1038/sj.ki.5002384
XuZG, YooTH, RyuDR, . Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int2005;67:944–52.doi:10.1111/j.1523-1755.2005.00158.x
11.
YooTH, LiJJ, KimJJ, . Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int2007;71:1019–27.doi:10.1038/sj.ki.5002195
12.
PagtalunanME, MillerPL, Jumping-EagleS, . Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest1997;99:342–8.doi:10.1172/JCI119163
13.
KrizW, GretzN, LemleyKV. Progression of glomerular diseases: is the podocyte the culprit?Kidney Int1998;54:687–97.doi:10.1046/j.1523-1755.1998.00044.x
14.
ChenHC, ChenCA, GuhJY, . Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci2000;67:2345–53.doi:10.1016/S0024-3205(00)00815-8
15.
NagataM. Podocyte injury and its consequences. Kidney Int2016;89:1221–30.doi:10.1016/j.kint.2016.01.012
16.
PozziA, JaradG, MoeckelGW, . Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity. Dev Biol2008;316:288–301.doi:10.1016/j.ydbio.2008.01.022
17.
TianX, KimJJ, MonkleySM, . Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance. J Clin Invest2014;124:1098–113.doi:10.1172/JCI69778
18.
RegoliM, BendayanM. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia1997;40:15–22.doi:10.1007/s001250050637
19.
SawadaK, ToyodaM, KaneyamaN, . Upregulation of α3β1-Integrin in Podocytes in Early-Stage Diabetic Nephropathy. J Diabetes Res2016;2016:1– 8.doi:10.1155/2016/9265074
20.
LiuBC, SongX, LuXY, . High glucose induces podocyte apoptosis by stimulating TRPC6 via elevation of reactive oxygen species. Biochim Biophys Acta2013;1833:1434–42.doi:10.1016/j.bbamcr.2013.02.031
21.
SchifferM, BitzerM, RobertsIS, . Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest2001;108:807–16.doi:10.1172/JCI200112367
22.
DasR, XuS, QuanX, . Upregulation of mitochondrial Nox4 mediates TGF-β-induced apoptosis in cultured mouse podocytes. Am J Physiol Renal Physiol2014;306:155–167.doi:10.1152/ajprenal.00438.2013
KrizW, ShiratoI, NagataM, . The podocyte's response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol2013;304:333–347.doi:10.1152/ajprenal.00478.2012
27.
ZhouT, HeX, ChengR, . Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy. Diabetologia2012;55:255–66.doi:10.1007/s00125-011-2314-2
28.
MacDonaldBT, TamaiK, HeX, . Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell2009;17:9–26.doi:10.1016/j.devcel.2009.06.016
29.
ZhouD, TanRJ, FuH, . Wnt/β-catenin signaling in kidney injury and repair: a double-edged sword. Lab Invest2016;96:156–67.doi:10.1038/labinvest.2015.153
30.
CleversH. Wnt/beta-catenin signaling in development and disease. Cell2006;127:469–80.doi:10.1016/j.cell.2006.10.018
31.
PulkkinenK, MuruganS, VainioS. Wnt signaling in kidney development and disease. Organogenesis2008;4:55–9.doi:10.4161/org.4.2.5849
32.
DenbyL, ConwayBR. Role of vascular endothelial growth factor in diabetic nephropathy. Am J Physiol Renal Physiol2016;58:104–12.
ZieglerS, RöhrsS, TickenbrockL, . Novel target genes of the Wnt pathway and statistical insights into Wnt target promoter regulation. Febs J2005;272:1600–15.doi:10.1111/j.1742-4658.2005.04581.x
35.
TanRJ, ZhouD, ZhouL, . Wnt/β-catenin signaling and kidney fibrosis. Kidney Int Suppl2014;4:84–90.doi:10.1038/kisup.2014.16
36.
KatoH, GruenwaldA, SuhJH, . Wnt/beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Mol Biochem2011;286:26003–15.
37.
HeW, TanRJ, LiY, . Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/β-catenin activity in CKD. J Am Soc Nephrol2012;23:294–304.doi:10.1681/ASN.2011050490
38.
HaoS, HeW, LiY, . Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol2011;22:1642–53.doi:10.1681/ASN.2010101079
39.
HeW, TanR, DaiC, . Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/beta-catenin signaling. J Biol Chem2010;285:24665–75.doi:10.1074/jbc.M109.091256
40.
MuJ, PangQ, GuoYH, . Functional implications of microRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PLoS One2013;8:1–13.doi:10.1371/journal.pone.0058622
41.
WangQ, WangY, MintoAW, . MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. Faseb J2008;22:4126–35.doi:10.1096/fj.08-112326
42.
AbrassCK. Diabetic nephropathy Mechanisms of mesangial matrix expansion. West J Med1995;162:318–21.
43.
LinCL, ChengH, TungCW, . Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt signaling pathway. Am J Nephrol2008;28:290–7.doi:10.1159/000111142
44.
SurendranK, McCaulSP, SimonTC. A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physiol2002;282:431–441.doi:10.1152/ajprenal.0009.2001
45.
MaezawaY, TakemotoM, YokoteK. Cell biology of diabetic nephropathy: roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig2015;6:3–15.doi:10.1111/jdi.12255
46.
LiZ, XuJ, XuP, . Wnt/β-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes. Cell Prolif2013;46:76–85.doi:10.1111/cpr.12010
47.
IlatovskayaDV, StaruschenkoA. TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases. Am J Physiol Renal Physiol2015;309:393–397.doi:10.1152/ajprenal.00186.2015
MeliambroK, JcH, CampbellKN. The podocyte as a therapeutic target in Proteinuric Kidney Disease. J Nephrol Ther2013;3:1–7.
50.
CuevasCA, Tapia-RojasC, CespedesC, . β -Catenin-Dependent signaling pathway contributes to renal fibrosis in hypertensive rats. Biomed Res Int2015;2015:1–13.doi:10.1155/2015/726012
51.
LiYC. Podocytes as target of vitamin D. Curr Diabetes Rev2011;7:35–40.
52.
ZhangY, DebDK, KongJ, . Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol2009;297:791–801.doi:10.1152/ajprenal.00247.2009
53.
HeW, KangYS, DaiC, . Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol2011;22:90–103.doi:10.1681/ASN.2009121236
54.
BudhirajaS, SinghJ. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. Fundam Clin Pharmacol2008;22:231–40.doi:10.1111/j.1472-8206.2008.00583.x
55.
ChaDR, KimNH, YoonJW, . Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl2000;77:104–12.
56.
TuttleKR, BakrisGL, TotoRD, . The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care2005;28:2686–90.doi:10.2337/diacare.28.11.2686
57.
ChenRH, DingWV, McCormickF. Wnt signaling to beta-catenin involves two interactive components. glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J Biol Chem2000;275:17894–9.doi:10.1074/jbc.M905336199
